Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsASX:RAD EV-to-EBIT is -0.05 as of Jul. 31, 2026. The stock has 5 warning signs investors should review. Among 382 Biotechnology companies, Radiopharm Theranostics ranks worse than 261779.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Radiopharm Theranostics's Enterprise Value for the quarter that ended in Jun. 2025 was A$20.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was A$-38.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics EV-to-EBIT Related Terms
Radiopharm Theranostics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAD vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's EV-to-EBIT falls into.
Radiopharm Theranostics's current Enterprise Value is A$2.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Radiopharm Theranostics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was A$-38.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (ASX:RAD) has a EV-to-EBIT of -0.05 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #999999 out of 382 companies in the Biotechnology industry.
Is Radiopharm Theranostics' EV-to-EBIT too high?
Radiopharm Theranostics' current EV-to-EBIT is -0.05. Based on the distribution chart, Radiopharm Theranostics ranks #999999 out of 382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #999999 out of 382 companies for EV-to-EBIT. This places Radiopharm Theranostics in the lower half of its industry. The industry median EV-to-EBIT is 12.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.56, based on 382 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current EV-to-EBIT is -0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current EV-to-EBIT of -0.05. The current EV-to-EBIT is -0.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current EV-to-EBIT is -0.05 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAD has been successfully added to your 
